Gilead declines 'rare disease' status for experimental coronavirus drug

NPR

25 March 2020 - In a surprising turnabout, drugmaker Gilead Sciences asked the FDA on Wednesday to rescind orphan status for remdesivir, the company's experimental coronavirus treatment.

The agency granted this status to remdesivir on Monday, prompting a backlash from public health and consumer advocates.

Orphan drug designation is intended to spur development of drugs for rare diseases by bestowing drugmakers with tax breaks, FDA fee waivers and seven years without generic competitors.

Read NPR article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Orphan drug